Marktanalyse - Allergic Conjunctivitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Allergic Conjunctivitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData's report, 'Allergic Conjunctivitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”, is an essential source of information and analysis on the global allergic conjunctivitis therapeutics market. The report identifies the key trends shaping and driving the global market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global allergic conjunctivitis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global allergic conjunctivitis therapeutics market was valued at $970m in 2010, which is expected to grow at a Compound Annual Growth Rate (CAGR) of 14.3% over the next eight years, to reach $2.8bn by 2018. The increase in disease awareness is expected to lead to a growth in the diagnosed and treated population which will be further complemented by rising compliance due to the availability of a sufficient number of treatment options including branded, generics and OTC (Over the Counter) products. The increase in the treated patient population, the increasing uptake of medications and the rising compliance will be the primary drivers for the growth of the allergic conjunctivitis therapeutics market in the future. There are no major pipeline products which are expected to drive the market. The major late stage products in the allergic conjunctivitis therapeutics pipeline are modified pollen extracts which cater to a niche population only.

Scope

The report provides information on the key drivers and challenges of the Allergic Conjunctivitis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Allergic Conjunctivitis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Allergic Conjunctivitis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Allergic Conjunctivitis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Allergic Conjunctivitis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Allergic Conjunctivitis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Allergic Conjunctivitis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Allergic Conjunctivitis Therapeutics market landscape? — Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Allergic Conjunctivitis Therapeutics: Introduction 7

2.1 Disease Overview 7

2.1.1 Intermittent or Seasonal Allergic Conjunctivitis (SAC) 7

2.1.2 Persistent or Perennial Allergic Conjunctivitis (PAC) 7

2.1.3 Vernal Keratoconjunctivitis (VKC) 7

2.1.4 Atopic Keratoconjunctivitis (AKC) 7

2.1.5 Giant Papillary Conjunctivitis (GPC) 7

2.2 Epidemiology 8

2.3 Etiology and Pathology 8

2.4 Signs and Symptoms 10

2.5 Diagnosis 10

2.6 Treatment and Management Pattern 11

2.6.1 Non-Pharmacological Intervention 11

2.6.2 Pharmacological Interventions 11

2.7 Referral Pathway 13

2.8 GlobalData Pipeline Report Guidance 14

3 Allergic Conjunctivitis Therapeutics: Market Characterization 15

3.1 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — Global 15

3.2 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — Global 16

3.3 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — The US 17

3.4 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — The US 18

3.5 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — France 19

3.6 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — France 20

3.7 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — Germany 21

3.8 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — Germany 22

3.9 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — Italy 23

3.10 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — Italy 24

3.11 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — Spain 25

3.12 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — Spain 26

3.13 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — The UK 27

3.14 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — The UK 28

3.15 Allergic Conjunctivitis Therapeutics Market Size (2005—2010) — Japan 29

3.16 Allergic Conjunctivitis Therapeutics Market Forecast (2010—2018) — Japan 30

3.17 Drivers and Barriers for the Allergic Conjunctivitis therapeutics market 31

3.17.1 Drivers for the Allergic Conjunctivitis therapeutics market 31

3.17.2 Barriers for the Allergic Conjunctivitis therapeutics market 31

3.17.3 Opportunity and Unmet need analysis 32

3.18 Key Takeaway 33

4 Allergic Conjunctivitis Therapeutics: Competitive Assessment 34

4.1 Overview 34

4.2 Strategic Competitor Assessment 34

4.3 Product Profiles for the Major Marketed Products in the Allergic Conjunctivitis Therapeutics Market 35

4.3.1 Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% 35

4.3.2 Patanol/Opatanol (olopatadine hydrochloride ophthalmic solution) 0.1% 36

4.3.3 Elestat (0.05% epinastine HCl ophthalmic solution) 38

4.3.4 Alomide (0.1% lodoxamide tromethamine ophthalmic solution) 39

4.3.5 Bepreve (1.5% bepotastine besilate ophthalmic solution) 39

4.3.6 Optivar (azelastine hydrochloride) 40

4.3.7 Lastacaft (alcaftadine ophthalmic solution) 41

4.4 Key Takeaway 42

5 Allergic Conjunctivitis Therapeutics: Pipeline Assessment 43

5.1 Overview 43

5.2 Strategic Pipeline Assessment 43

5.3 Allergic Conjunctivitis Therapeutics Pipeline — Pipeline by Phase of Development 43

5.3.1 Allergic Conjunctivitis Therapeutics — Phase III Pipeline 44

5.3.2 Allergic Conjunctivitis Therapeutics — Phase II Pipeline 44

5.3.3 Allergic Conjunctivitis Therapeutics — Discovery and Pre-Clinical Pipeline 44

5.3.4 Technology Trends Analytic Framework 45

5.4 Allergic Conjunctivitis Therapeutics Market —Pipeline by Mechanism of Action 47

5.5 Allergic Conjunctivitis Therapeutics — Promising Drugs under Clinical Development 48

5.6 Molecule Profile for Promising Drugs under Clinical Development 48

5.6.1 SCH 697243/ Grass Sublingual Tablet 48

5.6.2 SCH 039641 / Ragweed Sublingual Tablet 49

5.6.3 AC-170 49

5.6.4 DE-114 ophthalmic solution 49

5.7 Key Takeaway 50

6 Allergic Conjunctivitis Therapeutics: Clinical Trials Mapping 51

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 51

6.2 Clinical Trials by Phase 52

6.3 Clinical Trials by Trial Status 53

6.4 Prominent Sponsors 54

6.5 Top Companies Participating in Allergic Conjunctivitis Therapeutics Clinical Trials 56

7 Strategic Assessment 57

7.1 Key Events Impacting on the Future Market 57

7.2 Allergic Conjunctivitis Therapeutics: Implications for Future Market Competition 58

8 Allergic Conjunctivitis Therapeutics: Future Players 59

8.1 Introduction 59

8.2 Company Profiles 60

8.2.1 Merck & Co., Inc. 60

8.2.2 Aciex Therapeutics, Inc. 62

8.2.3 Santen Pharmaceutical Co., Ltd. 63

8.2.4 Other Companies in the Allergic Conjunctivitis Therapeutics Market 65

9 Allergic Conjunctivitis Therapeutics: Licensing and Partnership Deals 67

10 Allergic Conjunctivitis Therapeutics: Appendix 69

10.1 Market Definitions 69

10.2 Abbreviations 69

10.3 Methodology 70

10.3.1 Coverage 70

10.3.2 Secondary Research 71

10.3.3 Forecasting 71

10.3.4 Primary Research 74

10.3.5 Expert Panel Validation 74

10.4 Contact Us 74

10.5 Disclaimer 74

10.6 Bibliography 75



1.1 List of Tables

Table 1: Prevalence of Allergic Conjunctivitis by Country (G7) 8

Table 2: Allergic Conjunctivitis- Etiology 8

Table 3: Classification of Antiallergic Medications 11

Table 4: Allergic Conjunctivitis Therapeutics Market, Global, Revenue ($m), 2005—2010 15

Table 5: Allergic Conjunctivitis Therapeutics Market, Global, Forecast ($m), 2010—2018 16

Table 6: Allergic Conjunctivitis Therapeutics Market, the US, Revenue ($m), 2005—2010 17

Table 7: Allergic Conjunctivitis Therapeutics Market, the US, Forecasts ($m), 2010—2018 18

Table 8: Allergic Conjunctivitis Therapeutics Market, France, Revenue ($m), 2005—2010 19

Table 9: Allergic Conjunctivitis Therapeutics Market, France, Forecasts ($m), 2010—2018 20

Table 10: Allergic Conjunctivitis Therapeutics Market, Germany, Revenue ($m), 2005—2010 21

Table 11: Allergic Conjunctivitis Therapeutics Market, Germany, Forecasts ($m), 2010—2018 22

Table 12: Allergic Conjunctivitis Therapeutics Market, Italy, Revenue ($m), 2005—2010 23

Table 13: Allergic Conjunctivitis Therapeutics Market, Italy, Forecasts ($m), 2010—2018 24

Table 14: Allergic Conjunctivitis Therapeutics Market, Spain, Revenue ($m), 2005—2010 25

Table 15: Allergic Conjunctivitis Therapeutics Market, Spain, Forecasts ($m), 2010—2018 26

Table 16: Allergic Conjunctivitis Therapeutics Market, the UK, Revenue ($m), 2005—2010 27

Table 17: Allergic Conjunctivitis Therapeutics Market, the UK, Forecasts ($m), 2010—2018 28

Table 18: Allergic Conjunctivitis Therapeutics Market, Japan, Revenue ($m), 2005—2010 29

Table 19: Allergic Conjunctivitis Therapeutics Market, Japan, Forecasts ($m), 2010—2018 30

Table 20: Clinical study details 36

Table 21: Clinical study details 40

Table 22: Allergic Conjunctivitis Therapeutics, Phase III Pipeline, 2011 44

Table 23: Allergic Conjunctivitis Therapeutics, Phase II Pipeline, 2011 44

Table 24: Allergic Conjunctivitis Therapeutics, Preclinical Pipeline, 2011 44

Table 25: Allergic Conjunctivitis Therapeutics — Most Promising Drugs under Clinical Development, 2011 48

Table 26: Allergic Conjunctivitis Therapeutics, Clinical Trials by Country, 2011 51

Table 27: Allergic Conjunctivitis Therapeutics - Clinical Trials by Phase, 2011 52

Table 28: Allergic Conjunctivitis Therapeutics, Clinical Trials by Status, 2011 53

Table 29: Allergic Conjunctivitis Therapeutics, Prominent Sponsors, 2011 55

Table 30: Allergic Conjunctivitis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 56

Table 31: Merck & Co., Inc., Allergic Conjunctivitis Management, Pipeline, 2011 62

Table 32: Merck & Co., Inc., Ophthalmology, Pipeline, 2011 62

Table 33: Aciex Therapeutics, Inc., Allergic Conjunctivitis, Pipeline, 2011 62

Table 34: Santen Pharmaceutical Co., Ltd. — Allergic Conjunctivitis Management, Pipeline, 2011 64

Table 35: Santen Pharmaceutical Co., Ltd. — Ophthalmology, Pipeline, 2011 64

Table 36: Allergic Conjunctivitis Therapeutics Market, Future Players 65

Table 37: Allergic Conjunctivitis Therapeutics, Global, Deals, 2009-2011 67



1.2 List of Figures

Figure 1: Pathophysiology of Allergic Conjunctivitis 9

Figure 2: Diagnostic Techniques 10

Figure 3: Referral Pathway 13

Figure 4: Allergic Conjunctivitis Therapeutics Market, Global, Revenue ($m), 2005—2010 15

Figure 5: Allergic Conjunctivitis Therapeutics Market, Global, Forecast ($m), 2010—2018 16

Figure 6: Allergic Conjunctivitis Therapeutics Market, the US, Forecast ($m), 2005—2010 17

Figure 7: Allergic Conjunctivitis Therapeutics Market, the US, Forecast ($m), 2010—2018 18

Figure 8: Allergic Conjunctivitis Therapeutics Market, France, Revenue ($m), 2005—2010 19

Figure 9: Allergic Conjunctivitis Therapeutics Market, France, Forecast ($m), 2010—2018 20

Figure 10: Allergic Conjunctivitis Therapeutics Market, Germany, Revenue ($m), 2005—2010 21

Figure 11: Allergic Conjunctivitis Therapeutics Market, Germany, Forecast ($m), 2010—2018 22

Figure 12: Allergic Conjunctivitis Therapeutics Market, Italy, Revenue ($m), 2005—2010 23

Figure 13: Allergic Conjunctivitis Therapeutics Market, Italy, Forecast ($m), 2010—2018 24

Figure 14: Allergic Conjunctivitis Therapeutics Market, Spain, Revenue ($m), 2005—2010 25

Figure 15: Allergic Conjunctivitis Therapeutics Market, Spain, Forecast ($m), 2010—2018 26

Figure 16: Allergic Conjunctivitis Therapeutics Market, the UK, Revenue ($m), 2005—2010 27

Figure 17: Allergic Conjunctivitis Therapeutics Market, the UK, Forecast ($m), 2010—2018 28

Figure 18: Allergic Conjunctivitis Therapeutics Market, Japan, Revenue ($m), 2005—2010 29

Figure 19: Allergic Conjunctivitis Therapeutics Market, Japan, Forecast ($m), 2010—2018 30

Figure 20: Opportunity and Unmet Need in the Allergic Conjunctivitis Therapeutics Market, 2011 32

Figure 21: Allergic Conjunctivitis Therapeutics, Strategic Competitor Assessment, 2010 34

Figure 22: Allergic Conjunctivitis Therapeutics — Pipeline by Phase of Development, 2011 43

Figure 23: Allergic Conjunctivitis Therapeutics, Technology Trends Analytics Framework, 2011 45

Figure 24: Allergic Conjunctivitis Pipeline, Technology Trends Analytics Framework, Description, 2011 46

Figure 25: Allergic Conjunctivitis Therapeutics, Pipeline by Mechanism of Action, 2011 47

Figure 26: Allergic Conjunctivitis Therapeutics, Clinical Trials by Country, 2011 51

Figure 27: Allergic Conjunctivitis Therapeutics, Clinical Trials by Phase (%), 2011 52

Figure 28: Allergic Conjunctivitis Therapeutics, Clinical Trials by Status (%), 2011 53

Figure 29: Allergic Conjunctivitis Therapeutics, Overall Sponsors (%), 2011 54

Figure 30: Allergic Conjunctivitis Therapeutics, Prominent Sponsors (%), 2011 55

Figure 31: Allergic Conjunctivitis Therapeutics Market, Drivers and Restraints, 2011 57

Figure 32: Implications for Future Market Competition in the Allergic Conjunctivitis Therapeutics , 2011 58

Figure 33: Allergic Conjunctivitis Therapeutics Market, Pipeline by Company, 2011 59

Figure 34: GlobalData Market Forecasting Model 73

• Cough, Cold and Allergy (Hay Fever) Remedies in Australia
• Cough, Cold and Allergy (Hay Fever) Remedies in Croatia
• Cough, Cold and Allergy (Hay Fever) Remedies in Egypt
• Cough, Cold and Allergy (Hay Fever) Remedies in Romania
• Cough, Cold and Allergy (Hay Fever) Remedies in Saudi Arabia
• Cough, Cold and Allergy (Hay Fever) Remedies in Croatia
• Cough, Cold and Allergy (Hay Fever) Remedies in Slovenia
• Cough, Cold and Allergy (Hay Fever) Remedies in Kenya
• Cough, Cold and Allergy (Hay Fever) Remedies in Pakistan
• Cough, Cold and Allergy (Hay Fever) Remedies in Portugal
• Allergies – Pipeline Review, H2 2012
• Cough, Cold and Allergy (Hay Fever) Remedies in Iran
• Cough, Cold and Allergy (Hay Fever) Remedies in South Korea
• Cough, Cold and Allergy (Hay Fever) Remedies in the Netherlands
• Cough, Cold and Allergy (Hay Fever) Remedies in Uzbekistan
• Cough, Cold and Allergy (Hay Fever) Remedies in Vietnam
• Peanut Allergy – Pipeline Review, H2 2012
• Pollen Allergy – Pipeline Review, H2 2012
• Cough, Cold and Allergy (Hay Fever) Remedies in Algeria
• Cough, Cold and Allergy (Hay Fever) Remedies in Austria